S-DUAL®
S-DUAL® Bispecific Antibody Platform
S-DUAL®
The S-DUAL® bispecific antibody
platform delivers precise
heavy chain and light chain
pairing and produces
IgG-like bispecific
antibodies with >95%
purity. Its dual-specificity
therapeutic development
capabilities allow faster
commercialization while reducing risks
of low immunogenicity
antibodies.
This proprietary platform establishes an
optimal path for successful biologics
development. Discover related services
in ADC
(Antibody-Drug Conjugates) and
Analytical
Development.
Bispecific Antibody Platform Structure
-
- Low Immunogenicity Risk
-
- Similar structure to typical bispecific antibodies
- Antibody-derived protein only
-
- Correctly Paired bsAb
-
- Knob-into-Hole CH3 dimer applied on an additional domain in one Fab arm
- >95% purity
-
- Streamlined Access
-
- Favorable contract terms with competitive pricing
- Only parental antibody sequences needed to develop BsAb
A
B
Additional CH3 Domain
Knob-into-Hole
DEVELOPICK®
DEVELOPICK® Rapid Developability Assessment
DEVELOPICK®
DEVELOPICK® is a drug candidate
screening platform that
evaluates biologics in just one month
with minimal material (80 mg). Through
systematic biologics
developability assessment,
it scores drug candidates on stability,
solubility, and formulation potential.
Key features include:
· Primary structure assessment
· Relative solubility testing
· Stress treatments (heat, pH)
· Hydrophobic interaction analysis
· Comprehensive data reporting
This platform empowers early,
cost-efficient decision-making and
integrates seamlessly with Analytical
Development and Non-GMP / CGMP
Manufacturing.
Developability Assessment Workflow
DEVELOPICK® predicts candidates with the best potential for advancement by suggesting optimal formulation and scoring drug candidates based on stability screening.
- Material Supply
- Primary Structure Assessment
- Relative Solubility
- Basic Characterization
- Heat Stress Treatment
- Low & High pH Treatment
- Hydrophobic Interaction Analysis
- Data Reporting
- Material Supply
- Primary Structure Assessment
- Relative Solubility
- Basic Characterization
- Heat Stress Treatment
- Low & High pH Treatment
- Hydrophobic Interaction Analysis
- Data Reporting
S-CHOsient™
S-CHOsient™ Transient Expression System
S-CHOsient™
The S-CHOsient™ transient
expression system enables
early molecule generation and supports
CHO cell transient
expression workflows.
It allows researchers to:
· Produce material for internal
studies
· Test vector ratios for
transfection
· Generate reference material
for process development
With robust productivity and quality,
S-CHOsient™ strengthens early-stage
programs and accelerates
therapeutic antibody discovery
services. Learn more about
Biopharma
Development and Drug Product
Manufacturing.
Process Flow of S-CHOsient™
- Gene Synthesis / Vector Construction
- Transfection / Main Culture and Harvest
- Purification / Analytics
- Gene Synthesis / Vector Construction
- Transfection / Main Culture and Harvest
- Purification / Analytics
This streamlined process supports scalability and integration with Quality and Drug Substance Manufacturing.
Related Content
Accelerated Discovery with Advanced Platforms
Samsung Biologics provides advanced Late Discovery services that accelerate the transition from research to development. With our proprietary platforms, we help overcome scale-up challenges and enable faster, more efficient therapeutic antibody discovery services.
Our proprietary discovery technologies support bispecific antibody development and preclinical biologics development through three advanced platforms:
· S-DUAL® bispecific antibody platform
· DEVELOPICK® rapid developability assessment
· S-CHOsient™ transient expression system
By streamlining workflows, Samsung Biologics ensures that scale-up challenges are addressed early, helping clients bring innovations to market with speed and efficiency. Learn more about Process Development, Cell Line Development, and Biopharma Manufacturing.